The Sweet Protein That Could Follow Vanilla's Path to the Mass Market

Fermentation turned an obscure orchid bean into a $6 jar of extract. Brazzein — 1,500 times sweeter than sugar — may be next.

In the 1980s, the global vanilla market was in crisis. The hand-pollinated orchid pods from Madagascar, the world's only viable source of natural vanilla, sold for hundreds of dollars a kilogram. Food manufacturers paid the price or switched to artificial vanillin. Then synthetic biology arrived. By the early 2000s, the natural vanilla market had collapsed, prices fell below $40 per kilogram, and an ingredient that once sat in specialty stores migrated into virtually every processed food on earth.

A similar transformation may be underway for a sweet protein that, until recently, cost too much for anyone to use at commercial scale.

This week, Lithuanian startup Pentasweet broke ground on a €65 million ($76 million) precision fermentation facility in Vilnius — the first dedicated production plant for brazzein in Europe. The factory, covering more than 8,000 square meters in the Vilnius City Innovation Industrial Park, is expected to begin operations in the first half of 2027. Phase I will establish initial manufacturing capacity; Phase II will expand to the equivalent of 50,000 tons of sugar at full capacity, funded in part by a loan from Lithuania's national development bank, ILTE. Roughly 30 highly skilled jobs will be created.

Brazzein is a protein found in vanishingly small quantities in the fruit of the oubli shrub, a climbing plant native to Central and West Africa. It is approximately 1,500 times sweeter than sugar by weight — meaning a quantity invisible to the naked eye delivers the sweetness of an entire teaspoon. Unlike stevia, which many consumers find grassy or bitter, brazzein has a clean taste profile. Unlike monk fruit, which remains supply-constrained and expensive, precision fermentation allows it to be produced anywhere with the right organism and industrial capacity.

That capacity is now being built. Beyond Pentasweet, a handful of companies are scaling brazzein production using genetically engineered microbial hosts. Oobli (formerly Joywell Foods) — which in September 2025 received its third FDA "no questions" letter, this time for brazzein-54 — produces at contract manufacturing facilities using 200,000-liter fermentation tanks, primarily in Mexico, and has partnerships with Ingredion and Grupo Bimbo. Nanjing Bestzyme secured FDA GRAS status for its Aspergillus oryzae-produced brazzein in April 2025. MicroFarmtory, which produces a 90%-pure brazzein ingredient, says it can manufacture 30 metric tons per year today and is scaling toward 200 metric tons within two years.

The category is small but drawing real capital. Persistence Market Research projected the global brazzein market at approximately $612 million in 2026, up from roughly $507 million in 2020 — though other analysts put the 2026 figure lower, between $418 million and $655 million. The variance reflects genuine uncertainty about adoption speed, not a reliable data set.

What makes Pentasweet's bet plausible is the historical record of fermentation applied to scarce natural ingredients. The story of vanilla is the obvious reference point. The story of chymosin is the underappreciated one.

Fermentation-produced chymosin — the coagulant that sets milk into curds — replaced animal-derived rennet in cheese-making over roughly two decades. By 1999, approximately 60% of hard cheeses in the United States were made with fermentation-produced chymosin. By 2017, over 90% of the global cheese industry had switched. The transformation was near-total, driven entirely by economics and manufacturing consistency, not consumer preference or regulatory mandate.

The cost curve for precision fermentation has followed a similar trajectory. According to an analysis by Sweep, the cost of producing complex organic molecules via precision fermentation fell from approximately $1 million per kilogram in 2000 to around $100 per kilogram today. RethinkX has projected it could drop below $10 per kilogram within years. If that holds for brazzein, the economics that have kept it out of commercial food products become untenable — in both senses of the word.

The obstacles before that happens are real. Pentasweet will submit a food additive application to the European Food Safety Authority this year; approval is not guaranteed. The United States market, where Oobli already has regulatory clearance, remains years away for Pentasweet. The factory will not produce a commercial kilogram until 2027 at the earliest. And Pentasweet has disclosed no pricing for its eventual ingredient — an omission worth noting when MicroFarmtory's CEO has claimed his company's brazzein already costs the same in use as sugar. If that claim holds, it would be a genuine inflection point. If it doesn't, the facility in Vilnius is a very expensive bet on a price point not yet achieved.

For European food manufacturers, the attraction is clear: a domestically produced ultra-sweetener with heat and pH stability, a clean taste profile, and — critically — a final product containing no trace of its genetically engineered production host. Stevia formulations have improved, but many consumers still object to its taste. Monk fruit remains expensive and supply-variable. Brazzein, if it reaches cost parity, would offer a category of sweetness that is protein-derived, label-friendly, and scalable.

Whether Pentasweet is the company that gets it there is an open question. The facility is real. The loan from Lithuania's national development bank is real. The European regulatory filing is real. The price at which they can sell brazzein — and whether anyone will buy it — remains unknown.

Vanilla took thirty years to become a commodity. Brazzein's timeline will depend on whether the factories now being built can deliver what the laboratories promised.